Historical Valuation
Genmab A/S (GMAB) is now in the Fair zone, suggesting that its current forward PE ratio of 17.91 is considered Fairly compared with the five-year average of 38.27. The fair price of Genmab A/S (GMAB) is between 22.62 to 105.32 according to relative valuation methord.
Relative Value
Fair Zone
22.62-105.32
Current Price：34.21
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Genmab A/S (GMAB) has a current Price-to-Book (P/B) ratio of 3.37. Compared to its 3-year average P/B ratio of 3.68 , the current P/B ratio is approximately -8.50% higher. Relative to its 5-year average P/B ratio of 5.26, the current P/B ratio is about -35.98% higher. Genmab A/S (GMAB) has a Forward Free Cash Flow (FCF) yield of approximately 6.85%. Compared to its 3-year average FCF yield of 5.51%, the current FCF yield is approximately 24.41% lower. Relative to its 5-year average FCF yield of 4.09% , the current FCF yield is about 67.50% lower.
P/B
Median3y
3.68
Median5y
5.26
FCF Yield
Median3y
5.51
Median5y
4.09
Competitors Valuation Multiple
AI Analysis for GMAB
The average P/S ratio for GMAB competitors is 4.31, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB.O) exhibits a P/S ratio of 4.63, which is 7.32% above the industry average. Given its robust revenue growth of 25.25%, this premium appears sustainable.
Performance Decomposition
AI Analysis for GMAB
1Y
3Y
5Y
Market capitalization of GMAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GMAB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GMAB currently overvalued or undervalued?
Genmab A/S (GMAB) is now in the Fair zone, suggesting that its current forward PE ratio of 17.91 is considered Fairly compared with the five-year average of 38.27. The fair price of Genmab A/S (GMAB) is between 22.62 to 105.32 according to relative valuation methord.
What is Genmab A/S (GMAB) fair value?
GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Genmab A/S (GMAB) is between 22.62 to 105.32 according to relative valuation methord.
How does GMAB's valuation metrics compare to the industry average?
The average P/S ratio for GMAB's competitors is 4.31, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 4.63, which is 7.32% above the industry average. Given its robust revenue growth of 25.25%, this premium appears sustainable.
What is the current P/B ratio for Genmab A/S (GMAB) as of Jan 10 2026?
As of Jan 10 2026, Genmab A/S (GMAB) has a P/B ratio of 3.37. This indicates that the market values GMAB at 3.37 times its book value.
What is the current FCF Yield for Genmab A/S (GMAB) as of Jan 10 2026?
As of Jan 10 2026, Genmab A/S (GMAB) has a FCF Yield of 6.85%. This means that for every dollar of Genmab A/S’s market capitalization, the company generates 6.85 cents in free cash flow.
What is the current Forward P/E ratio for Genmab A/S (GMAB) as of Jan 10 2026?
As of Jan 10 2026, Genmab A/S (GMAB) has a Forward P/E ratio of 17.91. This means the market is willing to pay $17.91 for every dollar of Genmab A/S’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Genmab A/S (GMAB) as of Jan 10 2026?
As of Jan 10 2026, Genmab A/S (GMAB) has a Forward P/S ratio of 4.63. This means the market is valuing GMAB at $4.63 for every dollar of expected revenue over the next 12 months.